.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Daiichi Sankyo
Baxter
AstraZeneca
Farmers Insurance
Julphar
Deloitte
McKinsey
Express Scripts
Fuji

Generated: September 20, 2017

DrugPatentWatch Database Preview

Formoterol fumarate; glycopyrrolate - Generic Drug Details

« Back to Dashboard

What are the generic sources for formoterol fumarate; glycopyrrolate and what is the scope of formoterol fumarate; glycopyrrolate freedom to operate?

Formoterol fumarate; glycopyrrolate
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Formoterol fumarate; glycopyrrolate has seventy-six patent family members in twenty-five countries.

There are seventeen drug master file entries for formoterol fumarate; glycopyrrolate. One supplier is listed for this compound.

Summary for Generic Name: formoterol fumarate; glycopyrrolate

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list17
Suppliers / Packagers: see list1
Clinical Trials: see list801
Drug Prices:see low prices
DailyMed Link:formoterol fumarate; glycopyrrolate at DailyMed

Pharmacology for Ingredient: formoterol fumarate; glycopyrrolate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: formoterol fumarate; glycopyrrolate

Country Document Number Estimated Expiration
Taiwan201109051► Subscribe
South Africa201208100► Subscribe
World Intellectual Property Organization (WIPO)2010138862► Subscribe
Canada2763939► Subscribe
BrazilPI1011220► Subscribe
Slovenia2435023► Subscribe
Australia2010253950► Subscribe
Japan2012528199► Subscribe
Mexico2011012685► Subscribe
San MarinoT201600329► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FORMOTEROL FUMARATE; GLYCOPYRROLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02C/022Belgium► SubscribePRODUCT NAME: BUDESONID. MICRONIS. AND FORMOTEROL. FUMARAS DIHYDR., NATL REGISTRATION NO/DATE: 624 IS 234 F 0 20010129; FIRST REGISTRATION: SE 16047 20000825
C/GB02/033United Kingdom► SubscribePRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
QuintilesIMS
Citi
Baxter
Medtronic
AstraZeneca
Cerilliant
UBS
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot